- Home
- PALI vs SLN Comparison
PALI vs SLN Comparison
Compare PALI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | SLN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 300.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PALI | SLN |
|---|---|---|
| Price | $1.95 | $8.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $11.29 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 2.5M | 246.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $260,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | N/A |
| 52 Week Low | $0.55 | $4.19 |
| 52 Week High | $2.86 | $8.40 |
Technical Indicators
Market Signals| Indicator | PALI | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 68.50 |
| Support Level | $1.57 | $5.87 |
| Resistance Level | $2.12 | N/A |
| Average True Range (ATR) | 0.14 | 0.63 |
| MACD | 0.02 | 0.19 |
| Stochastic Oscillator | 75.00 | 96.32 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.